GENE ONLINE|News &
AstraZeneca’s Role in COVID-19 Slows Down as World Looks to mRNA Vaccines
After playing a defining role in early COVID-19 vaccine development, AstraZeneca’s contributions to the global vaccine market are coming to a close as governments worldwide, including the company’s home country, plan to leverage mRNA vaccines going forward. Declining sales are shedding light on a new mindset for the company. AstraZeneca’s CEO, Pascal Soriot, recently hinted at renewed focuses for the company and even opened up about his opinions on the need for boosters among general populations.
In the early days of the COVID-19 pandemic, companies were racing to develop a safe and effective vaccine to help quell the epidemic. AstraZeneca’s joint effort with Oxford University remained a focal point for the world among only a few other companies with the resources to develop such a vaccine.
AstraZeneca’s Decline in the COVID-19 Vaccine Market
In the early days of the COVID-19 pandemic, companies were racing to develop a safe and effective vaccine to help quell the epidemic. AstraZeneca’s joint effort with Oxford University remained a focal point for the world among only a few other companies with the resources to develop such a vaccine.
It's free! Log in now to read
LATEST
The Gene & Cell Therapy Landscape: Recent Approvals and Upcoming Therapeutics of Interest
2024-05-06
Exploring Key Areas of RNA Therapeutics Development: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
